Targeting vessels to treat hepatocellular carcinoma

Clinical Science

Volumn 114, Issue 7-8, 2008, Pages 467-477

  Romanque, Pamela ^a,b   Piguet, Anne Christine ^a   Dufour, Jean François ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSIDAD DIEGO PORTALES   (Chile)

Author keywords

Angiogenesis; Growth factor; Hepatocellular carcinoma (HCC); Inflammation; Liver; Vascular endothelial growth factor (VEGF)

Indexed keywords

ANGIOGENESIS INHIBITOR; AXITINIB; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; BMS 582664; CALCINEURIN; CEDIRANIB; CHIR 265; COMBRETASTATIN A4 PHOSPHATE; CYCLOPHOSPHAMIDE; DOCETAXEL; ENZASTAURIN; EVEROLIMUS; EXHERIN; FOCAL ADHESION KINASE; GENISTEIN; IRAGMIN; MITOGEN ACTIVATED PROTEIN KINASE; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PACLITAXEL; PAZOPANIB; PHOSPHOLIPASE C GAMMA; PI 88; PROTEIN KINASE C; SIGNALING LYMPHOCYTE ACTIVATION MOLECULE ASSOCIATED PROTEIN; SORAFENIB; TAMOXIFEN; THALIDOMIDE; TRANSCRIPTION FACTOR NFAT; TRANSFORMING GROWTH FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASOPRESSIN; VATALANIB; ANTINEOPLASTIC AGENT; TUMOR PROTEIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; CELL GROWTH; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED STUDY; CORPUS LUTEUM; EMBRYO DEVELOPMENT; ENDOMETRIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; ORGANOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TISSUE REPAIR; VASCULAR DISEASE; WOUND HEALING; LIVER TUMOR; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 41949122247     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20070310     Document Type: Review

References (107)

1. Coultas, L., Chawengsaksophak, K. and Rossant, J. (2005) Endothelial cells and VEGF in vascular development. Nature 438, 937-945
2. Dor, Y., Djonov, V. and Keshet, E. (2003) Making vascular networks in the adult: branching morphogenesis without a roadmap. Trends Cell Biol. 13, 131-136
3. Burri, P. H. and Djonov, V. (2002) Intussusceptive angiogenesis-the alternative to capillary sprouting. Mol. Aspects Med. 23, S1-S27
4. Jain, R. K. (2003) Molecular regulation of vessel maturation. Nat. Med. 9, 685-693
5. Jain, R. K. and Booth, M. F. (2003) What brings pericytes to tumor vessels? J. Clin. Invest. 112, 1134-1136
6. Fukumura, D. and Jain, R. K. (2007) Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc. Res. 74, 72-84
7. Ferrara, N. and Kerbel, R. S. (2005) Angiogenesis as a therapeutic target. Nature 438, 967-974
8. Carmeliet, P. (2005) Angiogenesis in life, disease and medicine. Nature 438, 932-936
9. Tanaka, S., Sugimachi, K., Yamashita, Y., Shirabe, K., Shimada, M. and Wands, J. R. (2003) Angiogenesis in life, disease and medicine. J. Gastroenterol. 38 (Suppl. 15), 93-97
10. Ribatti, D., Nico, B., Crivellato, E., Roccaro, A. M. and Vacca, A. (2007) The history of the angiogenic switch concept. Leukemia 21, 44-52
11. Ferrara, N., Gerber, H. P. and LeCouter, J. (2003) The biology of VEGF and its receptors. Nat. Med. 9, 669-676
12. Semela, D. and Dufour, J.-F. (2005) Vascular endothelial growth factor signaling. In Signaling Pathways in Liver Diseases (Dufour, J.-F. and Clavien, P. A., eds.), pp. 91-104, Springer, Berlin
13. Otrock, Z. K., Makarem, J. A. and Shamseddine, A. I. (2007) Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol. Dis. 38, 258-268
14. Huang, Z. and Bao, S. D. (2004) Roles of main pro- and anti-angiogenic factors in tumor angiogenesis. World J. Gastroenterol. 10, 463-470
15. Shibuya, M. (2006) Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J. Biochem. Mol. Biol. 39, 469-478
16. Semenza, G. L. (2003) Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3, 721-732
17. Xie, K., Wei, D., Shi, Q. and Huang, S. (2004) Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine Growth Factor Rev. 15, 297-324
18. Walczak, R., Joseph, S. B., Laffitte, B. A., Castrillo, A., Pei, L. and Tontonoz, P. (2004) Transcription of the vascular endothelial growth factor gene in macrophages is regulated by liver X receptors. J. Biol. Chem. 279, 9905-9911
19. Johnson, B. F., Clay, T. M., Hobeika, A. C., Lyerly, H. K. and Morse, M. A. (2007) Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. Expert Opin. Biol. Therapy 7, 449-460
20. Zhang, Y. W., Su, Y., Volpert, O. V. and Vande Woude, G. F. (2003) Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1. Proc. Natl. Acad. Sci. U.S.A. 100, 12718-12723
21. Parkin, D. M., Bray, F., Ferlay, J. and Pisani, P. (2001) Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 94, 153-156.
22. El-Serag, H. B. and Rudolph, K. L. (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132, 2557-2576
23. Llovet, J. M., Bru, C. and Bruix, J. (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 19, 329-338
24. Marrero, J. A., Fontana, R. J., Barrat, A. et al. (2005) Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 41, 707-716
25. Llovet, J. M., Sala, M. and Bruix, J. (2000) Nonsurgical treatment of hepatocellular carcinoma. Liver Transpl. 6, S11-S15
26. Lopez, P. M., Villanueva, A. and Llovet, J. M. (2006) Systematic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials. Aliment. Pharmacol. Ther. 23, 1535-1547
27. Varela, M., Sala, M., Llovet, J. M. and Bruix, J. (2003) Review article: natural history and prognostic prediction of patients with hepatocellular carcinoma. Aliment. Pharmacol. Ther. 17 (Suppl. 2), 98-102
28. Bruix, J. and Sherman, M. (2005) Management of hepatocellular carcinoma. Hepatology 42, 1208-1236
29. Semela, D. and Dufour, J. F. (2004) Angiogenesis and hepatocellular carcinoma. J. Hepatol. 41, 864-880
30. Gouysse, G., Couvelard, A., Frachon, S. et al. (2002) Relationship between vascular development and vascular differentiation during liver organogenesis in humans. J. Hepatol. 37, 730-740
31. Camenisch, G., Pisabarro, M. T., Sherman, D. et al. (2002) ANGPTL3 stimulates endothelial cell adhesion and migration via integrin αvβ3 and induces blood vessel formation in vivo. J. Biol. Chem. 277, 17281-17290
32. Novo, E., Cannito, S., Zamara, E. et al. (2007) Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. Am. J. Pathol. 170, 1942-1953
33. Jinno, K., Tanimizu, M., Hyodo, I. et al. (1998) Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma. J. Gastroenterol. 33, 376-382
34. Li, X. M., Tang, Z. Y., Zhou, G., Lui, Y. K. and Ye, S. L. (1998) Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 17, 13-17
35. Li, X., Tang, Z., Qin, L., Zhou, J. and Sun, H. (1999) Serum vascular endothelial growth factor is a predictor of invasion and metastasis in hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 18, 511-517
36. Yao, D. F., Wu, X. H., Zhu, Y. et al. (2005) Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int. 4, 220-226
37. Ng, I., Poon, R., Lee, J., Fan, S., Ng, M. and Tso, W. (2001) Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am. J. Clin. Pathol. 116, 838-845
38. Poon, R. T., Ng, I. O., Lau, C. et al. (2001) Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann. Surg. 233, 227-235.
39. Poon, R. T., Ho, J. W., Tong, C. S., Lau, C., Ng, I. O. and Fan, S. T. (2004) Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br. J. Surg. 91, 1354-1360
40. Kim, S. J., Choi, I. K., Park, K. H. et al. (2004) Serum vascular endothelial growth factor per platelet count in hepatocellular carcinoma: correlations with clinical parameters and survival. Jpn. J. Clin. Oncol. 34, 184-190
41. Chao, Y., Li, C. P., Chau, G. Y. et al. (2003) Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann. Surg. Oncol. 10, 355-362
42. Poon, R. T., Lau, C., Pang, R., Ng, K. K., Yuen, J. and Fan, S. T. (2007) High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann. Surg. Oncol. 14, 1835-1845
43. Kong, S. Y., Park, J. W., Lee, J. A. et al. (2007) Association between vascular endothelial growth factor gene polymorphisms and survival in hepatocellular carcinoma patients. Hepatology 46, 446-455
44. Sugimachi, K., Tanaka, S., Terashi, T., Taguchi, K. and Rikimaru, T. (2002) The mechanisms of angiogenesis in hepatocellular carcinoma: angiogenic switch during tumor progression. Surgery 131, S135-S141
45. Mitsuhashi, N., Shimizu, H., Ohtsuka, M. et al. (2003) Aneiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology 37, 1105-1113
46. Moon, W. S., Rhyu, K. H., Kang, M. J. et al. (2003) Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma? Mod. Pathol. 16, 552-557
47. Zhao, Z., Zheng, S., Wan, Y., Jia, C. and Xie, H. (2003) The molecular mechanism underlying angiogenesis in hepatocellular carcinoma: the imbalance activation of signaling pathways. Hepatobiliary Pancreat. Dis. Int. 2, 529-536
48. Yoshiji, H., Kuriyama, S., Noguchi, R. et al. (2005) Angiopoietin-2 displays vascular endothelial growth factor-dependent synergistic effect in hepatocellular carcinoma development in mice. Gut 54, 1768-1775
49. Llovet, J. M., Chen, Y., Wurmbach, E. et al. (2006) A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 131, 1758-1767
50. Horiguchi, N., Takayama, H., Toyoda, M. et al. (2002) Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine. Oncogene 21, 1791-1799
51. Son, G., Hirano, T., Seki, E. et al. (2006) Blockage of HGF/c-Met system by gene therapy (adenovirusmediated NK4 gene) suppresses hepatocellular carcinoma in mice. J. Hepatol. 45, 688-695
52. Imhof, B. A. and Aurrand-Lions, M. (2006) Angiogenesis and inflammation face off. 12, Nat. Med. 171-172
53. Arsura, M. and Cavin, L. G. (2005) Nuclear factor-κB and liver carcinogenesis. Cancer Lett. 229, 157-169
54. Elsharkawy, A. M. and Mann, D. A. (2007) Nuclear factor-κB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 46, 590-597
55. Pasparakis, M., Luedde, T. and Schmidt-Supprian, M. (2006) Dissection of the NF-κB signalling cascade in transgenic and knockout mice. Cell Death Differ. 13, 861-872
56. Bartoli, M., Platt, D. H., Lemtalsi, T. et al. (2003) VEGF differentially activates STAT3 in microvascular endothelial cells. FASEB J. 17, 1562-1564
57. Bartoli, M., Gu, X., Tsai, N. T. et al. (2000) Vascular endothelial growth factor activates STAT proteins in aortic endothelial cells J. Biol. Chem. 275, 33189-33192
58. Wincewicz, A., Sulkowska, M., Rutkowski, R. et al. (2007) STAT1 and STAT3 as intracellular regulators of vascular remodeling. Eur. J. Intern. Med. 18, 267-271
59. Izumi, R., Shimizu, K., Ii, T. et al. (1994) Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology 106, 720-727
60. Hodge, D. R., Hurt, E. M. and Farrar, W. L. (2005) The role of IL-6 and STAT3 in inflammation and cancer. Eur. J. Cancer Transcript. Factors Cancer 41, 2502-2512
61. Matsuzaki, K., Murata, M., Yoshida, K. et al. (2007) Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor? Signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology 46, 48-57
62. Fiedler, U., Reiss, Y., Scharpfenecker, M. et al. (2006) Angiopoietin-2 sensitizes endothelial cells to TNF-α and has a crucial role in the induction of inflammation. Nat. Med. 12, 235-239
63. El Awad, B., Kreft, B., Wolber, E.-M. et al. (2000) Hypoxia and interleukin-1β stimulate vascular endothelial growth factor production in human proximal tubular cells. Kidney Int. 58, 43-50
64. Hirota, K. and Semenza, G. L. (2006) Regulation of angiogenesis by hypoxia-inducible factor 1. Crit. Rev. Oncol. Hematol. 59, 15-26
65. Fang, J., Ding, M., Yang, L., Liu, L.-Z. and Jiang, B.-H. (2007) PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell. Signaling 19, 2487-2497
66. Shiota, G., Okubo, M., Noumi, T. et al. (1999) Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology 46, 407-412
67. Koga, H., Sakisaka, S., Ohishi, M. et al. (1999) Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 29, 688-696
68. Cheng, A., Chan, H., To, K. et al. (2004) Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virus-associated hepatocellular carcinoma. Int. J. Oncol. 24, 853-860
69. Leng, J., Han, C., Demetris, A. J., Michalopoulos, G. K. and Wu, T. (2003) Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 38, 756-768
70. Kern, M. A., Schoneweiss, M. M., Sahi, D. et al. (2004) Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice. Carcinogenesis 25, 1193-1199
71. Zhao, Q. T., Yue, S. Q., Cui, Z. et al. (2007) Potential involvement of the cyclooxygenase-2 pathway in hepatocellular carcinoma-associated angiogenesis. Life Sci. 80, 484-492
72. Lee, T. K., Poon, R. T., Yuen, A. P. et al. (2006) Rac activation is associated with hepatocellular carcinoma metastasis by up-regulation of vascular endothelial growth factor expression. Clin. Cancer Res. 12, 5082-5089
73. Ching, Y. P., Leong, V. Y., Lee, M. F., Xu, H. T., Jin, D. Y. and Ng, I. O. (2007) P21-activated protein kinase is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving c-Jun NH2-terminal kinase activation and paxillin phosphorylation. Cancer Res. 67, 3601-3608
74. Lee, T. K., Man, K., Ho, J. W. et al. (2005) FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma. Clin. Cancer Res. 11, 8458-8466
75. Lee, J. S., Semela, D., Iredale, J. and Shah, V. H. (2007) Sinusoidal remodeling and angiogenesis: a new function for the liver-specific pericyte? Hepatology 45, 817-825
76. Reference deleted
77. Zhang, T., Sun, H. C., Xu, Y. et al. (2005) Overexpression of platelet-derived growth factor receptor α in endothelial cells of hepatocellular carcinoma associated with high metastatic potential. Clin. Cancer Res. 11, 8557-8563
78. Fingar, D. C. and Blenis, J. (2004) Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23, 3151-3171
79. Guertin, D. A. and Sabatini, D. M. (2007) Defining the role of mTOR in cancer. Cancer Cell 12, 9-22
80. Sahin, F., Kannangai, R., Adegbola, O., Wang, J., Su, G. and Torbenson, M. (2004) mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin. Cancer Res. 10, 8421-8425
81. Sieghart, W., Fuereder, T., Schmid, K. et al. (2007) Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation 83, 425-432
82. Fingar, D. C., Richardson, C. J., Tee, A. R., Cheatham, L., Tsou, C. and Blenis, J. (2004) mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol. Cell. Biol. 24, 200-216
83. Shaw, R. J. and Cantley, L. C. (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441, 424-430
84. Guba, M., von Breitenbuch, P., Steinbauer, M. et al. (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 8, 128-135
85. Semela, D., Piguet, A. C., Kolev, M. et al. (2007) Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J. Hepatol. 46, 840-848
86. Hussain, S. P., Schwank, J., Staib, F., Wang, X. W. and Harris, C. C. (2007) TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 26, 2166-2176
87. Teodoro, J. G., Evans, S. K. and Green, M. R. (2007) Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J. Mol. Med. 85, 1175-1186
88. Folkman, J. (2006) Tumor suppression by p53 is mediated in part by the antiangiogenic activity of endostatin and tumstatin, Science STKE 2006, PE35
89. Kerbel, R. S. (2006) Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312, 1171-1175
90. Schwartz, J. D., Schwartz, M., Lehrer, D. et al. (2006) Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein. J. Clin. Oncol. 24 (Suppl. 18S), 4144
91. Zhu, A. X., Blaszkowsky, L. S., Ryan, D. P. et al. (2006) Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24, 1898-1903
92. Bertolotto, M., Pozzato, G., Croce, L. S. et al. (2006) Blood flow changes in hepatocellular carcinoma after the administration of thalidomide assessed by reperfusion kinetics during microbubble infusion: preliminary results. Invest. Radiol. 41, 15-21
93. Gordon, J. N. and Goggin, P. M. (2003) Thalidomide and its derivatives: emerging from the wilderness. Postgrad. Med. J. 79, 127-132
94. Patt, Y. Z., Hassan, M. M., Lozano, R. D. et al. (2005) Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer 103, 749-755
95. Lin, A. Y., Brophy, N., Fisher, G. A. et al. (2005) Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Cancer 103, 119-125
96. Zhu, A. X., Fuchs, C. S., Clark, J. W. et al. (2005) A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. Oncologist 10, 392-398
97. Arora, A. and Scholar, E. M. (2005) Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther. 315, 971-979
98. Strumberg, D. (2005) Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today 41, 773-784
99. Abou-Alfa, G. K., Schwartz, L., Ricci, S. et al. (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24, 4293-4300
100. Li, X., Feng, G. S., Zheng, C. S., Zhou, C. K. and Liu, X. (2004) Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J. Gastroenterol. 100, 2878-2882
101. Redaelli, C. A., Semela, D., Carrick, F. E. et al. (2004) Effect of vascular endothelial growth factor on functional recovery after hepatectomy in lean and obese mice. J. Hepatol. 40, 305-312
102. Geerts, A. M., De Vriese, A. S., Vanheule, E. et al. (2006) Increased angiogenesis and permeability in the mesenteric microvasculature of rats with cirrhosis and portal hypertension: an in vivo study. Liver Int. 26, 889-898
103. Moreau, R. (2005) VEGF-induced angiogenesis drives collateral circulation in portal hypertension. J. Hepatol. 43, 6-8
104. Fernandez, M., Mejias, M., Angermayr, B., Garcia-Pagan, J. C., Rodes, J. and Bosch, J. (2005) Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J. Hepatol. 43, 98-103
105. Fernandez, M., Mejias, M., Garcia-Pras, E., Mendez, R., Garcia-Pagan, J. C. and Bosch, J. (2007) Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. Hepatology 46, 1208-1217
106. Kamba, T. and McDonald, D. M. (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br. J. Cancer 96, 1788-1795
107. Longo, R. and Gasparini, G. (2007) Challenges for patient selection with VEGF inhibitors. Cancer Chemother. Pharmacol. 60, 151-170